<DOC>
	<DOC>NCT02712801</DOC>
	<brief_summary>This is a multi-center, randomized, controlled, open clinical trial. The trial will be carried out in five provinces in China. Pregnant women with HIV infection and at high risk of mother-to-child transmission of HIV will be identified. Their newborn babies who are at high risk HIV infection will be recruited and randomized into intervention and control groups. Children in intervention groups will receive ART and intensive HIV testing after birth. Children in control group will receive routine prevention of mother-to-child transmission services. All the included children will be followed up and their development and infection status will be recorded and compared.</brief_summary>
	<brief_title>Antiretroviral Regime for Viral Eradication in Newborns</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>children whose mother with HIV infection children whose mother received antiretroviral drugs after 36 gestational weeks or received no drugs before delivery live birth birth weight is less than 2000g Apgar score is less than 3 at 1 minute after birth or less than 6 at 5 minute after birth .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral treatment</keyword>
	<keyword>child</keyword>
	<keyword>testing</keyword>
</DOC>